Migraine and Vestibular Research

Migraine is a neurovascular disorder that affects over 1 billion people worldwide. Its widespread prevalence, and associated disability, have a range of negative and substantial effects not only on those immediately affected but also on their families, colleagues, employers, and society. To reduce this global burden, concerted efforts are needed to implement and improve migraine care that is supported by informed health-care policies.

Misdiagnoses of headache disorders are a serious issue. Therefore, we developed an artificial intelligence-based headache diagnosis model using a large questionnaire database in a specialized headache hospital.

Chronic migraine (CM) is a prevalent and disabling neurological disorder. Few prophylactic treatments for CM have been investigated. OnabotulinumtoxinA, which inhibits the release of nociceptive mediators, such as glutamate, substance P, and calcitonin gene-related peptide, has been evaluated in randomized, placebo-controlled studies for the preventive treatment of a variety of headache disorders, including CM.

Headaches are common in children and adolescents. Treatments for debilitating migraine are often not FDA approved or lack evidence of efficacy for children. This narrative review looks at the evidence for acute and preventative pharmacologic and non-pharmacologic treatment of pediatric migraine, as well as reviewing any recent or ongoing clinical trials.

This pooled analysis of data from four randomized placebo-controlled trials summarizes the efficacy and safety of rimegepant for acute treatment of migraine.

Post-traumatic stress disorder (PTSD) is a psychiatric disorder that develops and persists after an individual experiences a major traumatic or life-threatening event. While pharmacological treatment and psychological interventions can alleviate some symptoms, pharmacotherapy is time-consuming with low patient compliance, and psychological interventions are costly. Repetitive Transcranial Magnetic Stimulation (rTMS) is a safe and effective technique for treating PTSD, with advantages such as high compliance, low cost, and simplicity of implementation.

Chronic migraine (CM) is a debilitating neurological disorder with few treatment options. Peripheral nerve stimulation (PNS) of the occipital nerves is a potentially promising therapy for CM patients.

The Food and Drug Administration (FDA) has granted marketing authorization to CT-132, a prescription digital therapeutic developed by Click Therapeutics (New York, NY), for the preventive treatment of episodic migraine in adults. CT-132 is the first FDA-authorized prescription digital therapeutic (PDT) for this indication, offering a novel, nonpharmacologic option for people living with episodic migraine.

​Persistent Postural-Perceptual Dizziness (PPPD) is an increasingly recognized syndrome defined by enduring experiences of dizziness, unbalance, or non-vertiginous dizziness, generally persisting for a minimum of 3 months. This condition significantly impacts patients’ quality of life, highlighting the necessity for prompt and effective management. Vestibular rehabilitation therapy (VRT) has demonstrated efficacy in alleviating dizzy symptoms and enhancing balance. This meta-analysis seeks to assess the effectiveness of VRT in alleviating subjective dizzy symptoms and improving postural control in persons with PPPD.